SciSparc Ltd. (NASDAQ:SPRC) Short Interest Down 94.9% in June

SciSparc Ltd. (NASDAQ:SPRC) was the target of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 19,275 shares, a decrease of 94.9% from the May 31st total of 378,196 shares. Approximately 3.5% of the shares of the company are short sold. Based on an average daily trading volume, of 845,855 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of SciSparc in a report on Tuesday, May 26th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

SciSparc Stock Up 4.0%

NASDAQ:SPRC opened at $6.09 on Friday. The company has a 50-day moving average of $6.95 and a 200-day moving average of $7.60. SciSparc has a 52 week low of $2.98 and a 52 week high of $80.10.

SciSparc (NASDAQ:SPRC) last posted its earnings results on Wednesday, April 29th. The company reported ($31.60) earnings per share for the quarter. The company had revenue of $0.20 million for the quarter.

About SciSparc

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.